Improving immune response to vaccines by selective targeting of epithelial regions with the Nanopatch. Vaccination protects us from infections like measles and flu. In principle, it could protect us from all diseases, even from skin cancer and arthritis. In practice, however, vaccines to diseases like cancer have largely proved ineffective. One problem is that we don't really understand how the body's immune system responds to vaccination. Our aim, therefore, is to investigate changes in the imm ....Improving immune response to vaccines by selective targeting of epithelial regions with the Nanopatch. Vaccination protects us from infections like measles and flu. In principle, it could protect us from all diseases, even from skin cancer and arthritis. In practice, however, vaccines to diseases like cancer have largely proved ineffective. One problem is that we don't really understand how the body's immune system responds to vaccination. Our aim, therefore, is to investigate changes in the immune system when a vaccine enters the skin, as might happen by injection. Experimenting with laboratory mice and a special vaccine-injecting Nanopatch that is attached to each mouse's ear, we are starting to understand how a vaccine affects the immune cells in the skin. In the future we plan to apply this knowledge to improve vaccination in people.Read moreRead less
New Surfaces for the Control of Endothelial Cell Function: Application in the Design of Biocompatible Stents. Using dewetting of thin polymer films, the present proposal will develop new structured biocompatible surfaces with controlled chemistry and topography, which will allow the growth of a normal (non-activated) monolayer of endothelial cells. Sophisticated molecular parameters will be used to assess that endothelial cells maintain their normal quiescent phenotype. The project sets the grou ....New Surfaces for the Control of Endothelial Cell Function: Application in the Design of Biocompatible Stents. Using dewetting of thin polymer films, the present proposal will develop new structured biocompatible surfaces with controlled chemistry and topography, which will allow the growth of a normal (non-activated) monolayer of endothelial cells. Sophisticated molecular parameters will be used to assess that endothelial cells maintain their normal quiescent phenotype. The project sets the ground work for the design of improved, more biocompatible structured stents to minimise the abnormal growth of cells on and around the stent, thereby reducing the occurrence of vascular complications. Thus this research could improve the success rate of stents implanted into patients with cardiovascular disease and reduce health costs.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE180100043
Funder
Australian Research Council
Funding Amount
$435,279.00
Summary
High-throughput portable and wearable device fabrication facility. This project aims to establish a fabrication and characterisation facility for high-throughput production of portable, wearable and stretchable biomedical devices to accelerate the design–fabrication–evaluation process and save ‘trial-and-error’ costs during optimisation turnaround. It will apply computer-aided design for the programmable synthesis of hybrid materials for high-throughput screening of disease biomarkers, and super ....High-throughput portable and wearable device fabrication facility. This project aims to establish a fabrication and characterisation facility for high-throughput production of portable, wearable and stretchable biomedical devices to accelerate the design–fabrication–evaluation process and save ‘trial-and-error’ costs during optimisation turnaround. It will apply computer-aided design for the programmable synthesis of hybrid materials for high-throughput screening of disease biomarkers, and super-solution imaging of single molecules in live cells. This facility will provide capability for researchers pursuing industry transformation and other initiatives in the development of advanced materials, biomolecular sciences, nanotechnology, photonics and device engineering.Read moreRead less
Industrial Transformation Research Hubs - Grant ID: IH150100028
Funder
Australian Research Council
Funding Amount
$3,708,510.00
Summary
ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecu ....ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecules. The initial focus would be early diagnosis of disease and point-of-care drug testing for humans and animals, but the technology platform could be used to sample food and environmental toxins. The hub expects these disruptive technologies will make Australian biotechnology, diagnostics, veterinary, agribusiness and manufacturing firms globally competitive.Read moreRead less
Bacterial detection and infection control using tethered membranes. This project will develop a rapid diagnostic tool to detect live bacteria, which will subsequently reduce risk of infection, increase efficiencies in patient care and hospital management, and produce savings in health care budgets. It also has the potential to save lives through addressing the serious and growing problem of antibiotic resistance.
Attachment of Growth Factors to Pure, Plasma Modified and Coated Titanium Substrates. Titanium and its alloys are routinely used as medical and dental implants. Despite coating with hydroxyapatite, a material well known to improve implant fixation, many such implants fail because of lack of strong integration with bone. This proposal aims at achieving long-term stability of titanium implants through their surface modification and subsequent attachment of growth factors. The use of latter has alr ....Attachment of Growth Factors to Pure, Plasma Modified and Coated Titanium Substrates. Titanium and its alloys are routinely used as medical and dental implants. Despite coating with hydroxyapatite, a material well known to improve implant fixation, many such implants fail because of lack of strong integration with bone. This proposal aims at achieving long-term stability of titanium implants through their surface modification and subsequent attachment of growth factors. The use of latter has already been shown to help bone-implant integration. Successful project implementation will provide titanium implant surfaces that will help achieve speedier and improved implant fixation with long-term stability. Knowledge, expertise and techniques developed will help the industry partner expanding its research base and business and generating wealth in Australia. Training of world-class research students in the emerging field of biotechnology will be another major outcome.Read moreRead less
Development Of A Fibre-optic Flow Sensor To Monitor Blood Platelet Adhesive Function.
Funder
National Health and Medical Research Council
Funding Amount
$187,550.00
Summary
The ability to accurately diagnose platelet dysfunction is key to the clinical management of many cardiovascular diseases which represent a major cause of mortality in the industrialised world. At present there is no clinically robust instrument that can accurately assess abnormal platelet function under conditions that closely mimic the physiological environment. We aim to develop a sensitive prototype instrument for the clinical assessment of platelet function. We propose to develop this medic ....The ability to accurately diagnose platelet dysfunction is key to the clinical management of many cardiovascular diseases which represent a major cause of mortality in the industrialised world. At present there is no clinically robust instrument that can accurately assess abnormal platelet function under conditions that closely mimic the physiological environment. We aim to develop a sensitive prototype instrument for the clinical assessment of platelet function. We propose to develop this medical device as a relatively cheap and portable point of care instrument that can be marketed internationally.Read moreRead less
Benign fabrication of microfluidic hydrogel for improved artificial vasculature in bone implants. We will create a benign technology for synthesising microfluidic hydrogels to generate artificial vascultures in bone implants. It is a critical step to enable the use of tissue-engineered vital organs, such as bone, heart and kidney in patients with end-stage organ failure. Thicker scaffolds will be possible, as the vasculature will provide nutrients and oxygen for cells to grow into 3D scaffolds. ....Benign fabrication of microfluidic hydrogel for improved artificial vasculature in bone implants. We will create a benign technology for synthesising microfluidic hydrogels to generate artificial vascultures in bone implants. It is a critical step to enable the use of tissue-engineered vital organs, such as bone, heart and kidney in patients with end-stage organ failure. Thicker scaffolds will be possible, as the vasculature will provide nutrients and oxygen for cells to grow into 3D scaffolds. It will promote capacity of Australia for manufacturing global biomaterial products for tissue engineering. We will also develop in-situ imaging analytical protocols for the rapid analysis of broad arrays of functional molecules, with significant bearing on BioMEMS design to develop methods for diagnosis of fatal diseases.Read moreRead less
Biomaterial applications of synthetic elastin. The grant will develop a new collaboration between two established laboratories. The Weiss Lab (synthetic elastin; University of Sydney, Australia) will send elastin materials to the Langer Lab (interface of biotechnology and materials science; MIT, USA). Prof. Weiss will visit the Langer Lab and be trained in and participate collaboratively in the use of established MIT methodologies that will focus on applications in cardiac tissue engineering, co ....Biomaterial applications of synthetic elastin. The grant will develop a new collaboration between two established laboratories. The Weiss Lab (synthetic elastin; University of Sydney, Australia) will send elastin materials to the Langer Lab (interface of biotechnology and materials science; MIT, USA). Prof. Weiss will visit the Langer Lab and be trained in and participate collaboratively in the use of established MIT methodologies that will focus on applications in cardiac tissue engineering, controlled release of drugs and vocal fold repair. The MIT group will benefit from access to and the use of elastin materials that are developed in AustraliaRead moreRead less
Modulation of protein folding pathways: a new platform technology for molecular medicine. Misfolding of proteins is becoming recognised as a major cause of inherited disease. We propose to develop a chemical agent that will optimise the folding of alpha1-antitrypsin (AAT), misfolding of which gives rise to inheritable liver and lung disease. This agent will have potential application as a therapy for sufferers of AAT-misfolding disease and for improving the yield of AAT purified from human plasm ....Modulation of protein folding pathways: a new platform technology for molecular medicine. Misfolding of proteins is becoming recognised as a major cause of inherited disease. We propose to develop a chemical agent that will optimise the folding of alpha1-antitrypsin (AAT), misfolding of which gives rise to inheritable liver and lung disease. This agent will have potential application as a therapy for sufferers of AAT-misfolding disease and for improving the yield of AAT purified from human plasma, which is the current agent used to treat patients with AAT-misfolding disease.Read moreRead less